Chronic wound biotech raises $26M in Series D to expand blood clot products

Katherine Lewin

News Reporter

Wound care company RedDress, whose products heal chronic wounds using the patient’s own blood, has raised $26 million in a Series D funding round. The …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Chronic wound biotech raises $26M in Series D to expand blood clot products

Katherine Lewin

News Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

FDA plans to ban pharma employees from serving on adcomms. The impact will be limited

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Chron­ic wound biotech rais­es $26M in Se­ries D to ex­pand blood clot prod­ucts

News Reporter

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Chronic wound biotech raises $26M in Series D to expand blood clot products